uniQure N.V. (QURE) shares tumbled 36.58 percent to $9.91, down $5.72 on Monday, after the company reported a full-year net loss and disclosed FDA feedback indicating that current Phase 1/2 data for AMT-130 in Huntington's disease are insufficient to support a marketing application.
The stock is currently trading at $9.91, compared with a previous close of $15.63. It opened at $9.19 and has traded between $8.96 and $10.28 during the session on the Nasdaq. Trading volume stands at 8.53 million shares, well above its average volume of 2.64 million shares.
For full year 2025, revenue declined to $16.1 million from $27.1 million in 2024. Net loss narrowed to $199.0 million, or $3.46 per share, from $239.6 million, or $4.92 per share, a year earlier. The stock has traded in a 52-week range of $7.76 to $71.50.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.